ALK-1 receptor: New target in angiogenesis

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

Pfizer Oncology is working with a fully human, IgG2 monoclonal antibody (PF-03446962) that is directed against an activin-like receptor kinase 1 (ALK-1) target. An early investigation indicates that neutralizing ALK-1 with PF-03446962 can disturb tumor endothelial cell function and impair tumor angiogenesis, according to the company (AACR 2009 abstract 2007).

Pfizer Oncology is working with a fully human, IgG2 monoclonal antibody (PF-03446962) that is directed against an activin-like receptor kinase 1 (ALK-1) target. An early investigation indicates that neutralizing ALK-1 with PF-03446962 can disturb tumor endothelial cell function and impair tumor angiogenesis, according to the company (AACR 2009 abstract 2007).

Articles in this issue
ADT in prostate ca increases risk of bone and heart complications
Abraxis backs SPARC as prognostic biomarker
ALK-1 receptor: New target in angiogenesis
Abraxane prolongs PFS in metastatic disease
SAVI applicator removes obstacles associated with brachytherapy
Mistrust, costs reduce breast cancer screening among minorities
Oral chemotherapy poses more challenges for cancer community
CMS nixes CT colonography screening
New ultrasound strategy helps pinpoint prostate tumors
New research on VEGF, gene mutations refines understanding of tumor angiogenesis
From the ONI archives: Should low-dose induction dexamethasone be standard of care in multiple myeloma?
Persistent circulating tumor cells predict worse outcomes in early breast cancer
Genomics takes center stage at AACR in chemoprevention and disease treatment
Gefitinib changes first-line Rx for lung ca in Asian pts
Who's News
Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Related Content
Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers

Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers

ONCOLOGY Staff
March 14th 2025
Article

Results from the CheckMate649 trial support the use of nivolumab plus chemotherapy in the treatment of advanced gastric cancers.

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
March 10th 2025
Podcast

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.

Highlighting Developments and Informing Treatment Planning in CLL Care

Roman Fabbricatore
March 13th 2025
Article

Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
March 7th 2025
Podcast

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

New Cohort Approved in Phase 1/2 Trial of TTX-MC138 in Solid Cancers

New Cohort Approved in Phase 1/2 Trial of TTX-MC138 in Solid Cancers

Tim Cortese
March 13th 2025
Article

Based on positive safety data from the third cohort, a safety review committee approved the opening of a fourth cohort as well as more enrollment into the third cohort.

Five-Year Impact of the COVID-19 Pandemic on the Oncology Community

Five-Year Impact of the COVID-19 Pandemic on the Oncology Community

ONCOLOGY Staff
March 13th 2025
Article

Leading multidisciplinary oncology professionals look back at how the COVID-19 pandemic changed cancer care.